TLDR Bitcoin climbed ~5% to $71,418, lifting crypto-linked stocks including Strategy (+8%), Coinbase (+7%), and Riot Platforms (+4%) Moderna settled a $950M patentTLDR Bitcoin climbed ~5% to $71,418, lifting crypto-linked stocks including Strategy (+8%), Coinbase (+7%), and Riot Platforms (+4%) Moderna settled a $950M patent

Today’s Market Movers: Bitcoin Lifts Strategy, Coinbase, and Riot as Moderna Settles $950M Patent Case

2026/03/04 19:19
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

TLDR

  • Bitcoin climbed ~5% to $71,418, lifting crypto-linked stocks including Strategy (+8%), Coinbase (+7%), and Riot Platforms (+4%)
  • Moderna settled a $950M patent dispute over its COVID-19 vaccine, less than investors feared
  • Ross Stores beat Q4 earnings and raised guidance, shares jumped up to 7.5%
  • GitLab dropped ~9% despite a Q4 earnings beat, after issuing weaker-than-expected annual revenue guidance
  • Horizon Technology Finance fell 10% after total investment income missed estimates at $20.7M vs $23.9M expected

Bitcoin bounced back sharply on Wednesday, rising about 5% to around $71,418. That move pulled crypto-related stocks higher across the board.

Strategy gained 8%, Coinbase rose around 7%, and MARA Holdings was up 7%. Riot Platforms, Robinhood Markets, Galaxy Digital, and Hut 8 all gained between 4% and 5%. Circle Internet Group also added 6%.


COIN Stock Card
Coinbase Global, Inc., COIN

The crypto rally came after a period of selling tied to rising Middle East tensions. Investors appeared to shift back into risk assets as markets stabilized somewhat.

Gold miners also gained on Wednesday. Newmont climbed 2.8% and Freeport-McMoRan rose 1.9%, as uncertainty in the Middle East pushed some investors toward safe-haven assets including gold.

Moderna Settles Patent Case for $950M

Moderna reached a $950 million settlement with Arbutus Biopharma and Genevant Sciences. The case was tied to patent disputes over its COVID-19 and RSV vaccines.

The settlement was seen as a relief by investors, who had feared a much larger payout. Moderna’s COVID-19 vaccine has generated between $45 billion and $50 billion in revenue.

The payment is due in Q3 and will be recorded as a Q1 charge. After the settlement, Moderna expects to end the year with $4.5 billion to $5 billion in cash.

Moderna will still appeal to the U.S. Federal Circuit. A favorable ruling could remove any additional payment, but an adverse decision could require up to $1.3 billion more within 90 days.

Ross Stores had a strong day, rising up to 7.5% in premarket trading. The retailer beat Q4 earnings estimates and issued guidance well above Wall Street expectations for the coming quarter.

For Q1, Ross expects comparable sales growth of 7% to 8%, versus analyst estimates of about 3.7%. The company also raised its dividend by 10%.

GitLab and Horizon Slide on Weak Outlooks

GitLab fell around 8.5% to 9% despite beating Q4 earnings. The company’s full-year revenue guidance of $1.099 billion to $1.118 billion came in below the $1.13 billion consensus.

CEO Bill Staples said the company was not satisfied with its revenue guidance and outlined five steps to improve growth.

Horizon Technology Finance dropped 10% after reporting total investment income of $20.7 million, short of the $23.9 million estimate. Net asset value per share also edged lower during the quarter.

CrowdStrike edged up 1.1% after beating Q4 earnings and revenue estimates. Box gained 6.2% after topping Wall Street targets and issuing solid guidance for the current quarter.

Broadcom was up 1% ahead of its fiscal first-quarter earnings report after the closing bell, with analysts expecting its semiconductor revenue to rise 51% year over year.

The post Today’s Market Movers: Bitcoin Lifts Strategy, Coinbase, and Riot as Moderna Settles $950M Patent Case appeared first on CoinCentral.

Market Opportunity
Audiera Logo
Audiera Price(BEAT)
$0.28245
$0.28245$0.28245
+8.65%
USD
Audiera (BEAT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.